Ann: Nuheara Clinical Trial and FDA 510(K) Pathway Update, page-5

FDA approval as a medical device opens up a massive market with devices selling for $1500-$2500 and being built for $100. I like those margins.

Sure the SP has been battered by Perennial value. I have seen this happen so many times with these guys and Regal. A few months after they finish selling the market bounces back. Especially if the fundamentals are in place. NUH has those fundamentals in spade lined up for 2022.

IMHO, we will sit at 1.5- 1.7 until the SPP is complete. The report at the end of Jan should be welcomed by new investor eyes, and a move through 2c.